☆ 4.3 Article

Real world study of ocrelizumab in multiple sclerosis: Kuwait experience

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Effectiveness of ocrelizumab on clinical and MRI outcome measures in multiple sclerosis across black and white cohorts: A single-center retrospective study

Amanda Frisosky Abuaf et al.

Summary: This study aimed to examine differences in the therapeutic response to ocrelizumab in self-identified White and Black multiple sclerosis (MS) patients by assessing expanded disability status scale (EDSS) progression and MRI brain volume loss longitudinally. The conclusion was that despite higher baseline disability in the Black cohort, ocrelizumab treatment was equally effective in stabilizing clinical and MRI measures of disease progression in both Black and White patients.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

Add to Collection

Article Clinical Neurology

Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: An observational study in the Middle East

Raed Alroughani et al.

Summary: This cross-sectional hospital records-based study evaluated the prevalence, severity, outcomes, and risk factors of COVID-19 in MS patients. The majority of MS patients with COVID-19 had mild illness and made a full recovery. High EDSS scores, progressive MS disease, and use of anti-CD20 therapy were identified as risk factors for moderate to severe COVID-19 requiring hospitalization. Comorbidities were associated with a higher risk of non-recovery from COVID-19. Age, sex, smoking history, and duration of MS did not show a significant association with severity or adverse COVID-19 disease outcome.

JOURNAL OF CLINICAL NEUROSCIENCE (2022)

Add to Collection

Article Medicine, General & Internal

Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study

Roberta Lanzillo et al.

Summary: The study demonstrates that early ocrelizumab treatment is effective in modifying disability accrual in MS patients.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Clinical Neurology

Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population

Eva Fernandez-Diaz et al.

Summary: The study evaluated the safety and effectiveness of ocrelizumab treatment for multiple sclerosis in a real-world clinical setting. Results showed excellent suppression of disease activity with a favorable safety profile.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

COVID-19 in ocrelizumab-treated people with multiple sclerosis

Richard Hughes et al.

Summary: Limited data on the impact of COVID-19 on people with MS, especially those treated with ocrelizumab, show that most cases are mild and there is no clear association between ocrelizumab exposure duration and COVID-19 severity.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Real-world experience of ocrelizumab in multiple sclerosis in an Arab population

Beatriz Garcia-Canibano et al.

Summary: The study evaluated the safety and effectiveness of ocrelizumab treatment for multiple sclerosis in an Arab population in a real-world clinical setting. Results showed good efficacy, tolerability, and safety of ocrelizumab in this population.

JOURNAL OF DRUG ASSESSMENT (2021)

Add to Collection

Article Clinical Neurology

Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study

Kyle Smoot et al.

Summary: The study aimed to evaluate the safety and treatment outcomes of ocrelizumab in a community-based MS population. Results showed that ocrelizumab effectively controlled relapse risk and disability worsening, but infections leading to hospitalizations, especially in older and disabled patients, remained a concern despite a low discontinuation rate of the treatment.

BMJ NEUROLOGY OPEN (2021)

Add to Collection

Article Neurosciences

Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America

Juan Ignacio Rojas et al.

Summary: This study investigated patient profiles, effectiveness, and persistence with ocrelizumab treatment in Latin America for multiple sclerosis. Results showed that the majority of patients had relapsing-remitting MS, and 75% were free from clinical relapses after using ocrelizumab. Overall, the study findings are consistent with previous clinical trials and real-world studies.

ARQUIVOS DE NEURO-PSIQUIATRIA (2021)

Add to Collection

Review Clinical Neurology

Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines

B. Yamout et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

Add to Collection

Article Clinical Neurology

Ocrelizumab initiation in patients with MS A multicenter observational study

Erik Ellwardt et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)

Add to Collection

Article Clinical Neurology

Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients

Victoria Prockl et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2020)

Add to Collection

Article Clinical Neurology

Five years of ocrelizumab in relapsing multiple sclerosis OPERA studies open-label extension

Stephen L. Hauser et al.

NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis

Benjamin Turner et al.

JOURNAL OF NEUROLOGY (2019)

Add to Collection

Article Clinical Neurology

Data quality evaluation for observational multiple sclerosis registries

Tomas Kalincik et al.

MULTIPLE SCLEROSIS JOURNAL (2017)

Add to Collection

Article Clinical Neurology

Data quality evaluation for observational multiple sclerosis registries

Tomas Kalincik et al.

MULTIPLE SCLEROSIS JOURNAL (2017)

Add to Collection

Article Medicine, General & Internal

Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function

Daniel Ontaneda et al.

LANCET (2017)

Add to Collection

Article Medicine, General & Internal

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

S. L. Hauser et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

X. Montalban et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Review Clinical Neurology

The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects

Per Soelberg Sorensen et al.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2016)

Add to Collection

Article Cell Biology

Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy

Rui Li et al.

SCIENCE TRANSLATIONAL MEDICINE (2015)

Add to Collection

Review Clinical Neurology

Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

Gavin Giovannoni et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)

Add to Collection

Editorial Material Clinical Neurology

Disease Activity Free Status A New End Point for a New Era in Multiple Sclerosis Clinical Research?

Carolyn J. Bevan et al.

JAMA NEUROLOGY (2014)

Add to Collection

Article Medicine, Research & Experimental

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

Christian Klein et al.

MABS (2013)

Add to Collection

Editorial Material Clinical Neurology

Disease activity free status in MS

Fred D. Lublin

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2012)

Add to Collection

Article Clinical Neurology

Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria

Chris H. Polman et al.

ANNALS OF NEUROLOGY (2011)

Add to Collection

Article Clinical Neurology

Pediatric Multiple Sclerosis

Tanuja Chitnis et al.

NEUROLOGIC CLINICS (2011)

Add to Collection

Article Clinical Neurology

Clinical features and viral serologies in children with multiple a multinational observational study

Brenda Banwell et al.

LANCET NEUROLOGY (2007)

Add to Collection

Article Clinical Neurology

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

J Río et al.

ANNALS OF NEUROLOGY (2006)

Add to Collection

Article Clinical Neurology

Effect of relapses on development of residual deficit in multiple sclerosis

FD Lublin et al.

NEUROLOGY (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.